Nav: Home

'Reporter islets' in the eye may predict autoimmunity in type 1 diabetes

May 14, 2019

Identifying a reliable biomarker to predict the onset of autoimmunity in type 1 diabetes (T1D) has eluded scientists. As a result, T1D is typically diagnosed long after the majority of insulin-producing cells have been irreversibly destroyed. Unlike the onset of other autoimmune diseases which can be seen on the body or felt through symptoms, the attack on the islets cannot be observed because they reside deep within the pancreas.

Now scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine have shown that islets transplanted in the anterior chamber of the eye (ACE) may be reliable reporters of type 1 diabetes development and progression elsewhere in the body. In a study conducted in a rodent model of type 1 diabetes, the researchers showed that ACE-transplanted islets exhibit early signs of inflammation well before the manifestation of diabetes symptoms. If scientists could detect the start of islet destruction early enough, it could allow for timely interventions to halt or delay the further loss of the islet cells at the inception of the disease or before recurrence of autoimmunity after islet transplantation. The results are published online in Diabetologia, the journal of the European Association for the Study of Diabetes (EASD).

Observing Diabetes Progression in Real Time

Using a previously established approach that they pioneered, study co-authors Midhat Abdulreda, Ph.D., DRI assistant professor of surgery, and Per-Olof Berggren, Ph.D., Mary Lou Held Visiting Scientist and adjunct professor of surgery at the DRI, and director of the Rolf Luft Research Center for Diabetes and Endocrinology at the Karolinska Institutet in Stockholm, Sweden, and their team studied in real time transplanted islets within the ACE of mice before, during and after type 1 diabetes development. The team found that during diabetes onset, islet grafts in the eye were attacked by the immune system in a similar way to islets transplanted in the kidney as well as to native islets of the pancreas. Additionally, the infiltration of the immune cells in all three locations coincided with the hallmarks of autoimmunity, namely early islet inflammation and the later onset of hyperglycemia.

Guiding Timely Intervention

Guided by the early signals from reporter islets, the team tested two approaches for halting the attack against the insulin-producing cells. First, they administered short-term systemic treatment with anti-CD3 monoclonal antibody, an immunosuppressive agent that prevents rejection, which significantly delayed the progression of type 1 diabetes compared to controls.

Next, they explored localized immunosuppression within the eye in which the islets were transplanted, a potentially safer alternative to systemic treatment, which also significantly prolonged the survival of the cells.

"The current research highlights the potential of ACE-islets in guiding and improving the development of new treatment modalities in type 1 diabetes prevention, as well as in transplant applications, with the goal of eliminating systemic immunosuppression," said Dr. Abdulreda.

"Our findings demonstrate the value of islet transplants in the eye to study early type 1 diabetes pathogenesis in vivo and underscore the need for timely intervention to halt disease progression," said Dr. Berggren.

In type 1 diabetes, the insulin-producing islets cells of the pancreas have been mistakenly destroyed by the immune system, requiring patients to manage their blood sugar levels through a daily regimen of insulin therapy. Islet transplantation has restored natural insulin production in people with T1D, as DRI scientists have published. However, patients who receive islet transplants require life-long immunosuppression to prevent rejection of the donor cells. Not only does extended use of anti-rejection drugs pose serious side effects, but the immune attack against the transplanted islets can still occur despite the use of these agents. DRI scientists have been investigating ways to reduce or eliminate the need for anti-rejection therapy, one of the major research challenges which stands in the way of a biological cure for T1D.

"Combined with resulting data from our upcoming Phase I/II intraocular islet transplant clinical trial, this study could help inform future clinical studies aimed at reducing anti-rejection therapy," said Dr. Abdulreda.
-end-
About the Diabetes Research Institute

The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production and normalizing blood sugar levels without imposing other risks. Researchers have already shown that transplanted islet cells allow patients to live without the need for insulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes through its BioHub strategy, a multidisciplinary, three-pronged approach for addressing the major challenges that stand in the way of a cure: eliminate the need for anti-rejection drugs, reset the immune system to block autoimmunity, and develop an unlimited supply of insulin-producing cells. For more information, please visit DiabetesResearch.org, call 800-321-3437, or Tweet @Diabetes_DRI.

Diabetes Research Institute Foundation

Related Diabetes Articles:

The role of vitamin A in diabetes
There has been no known link between diabetes and vitamin A -- until now.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
Type 2 diabetes and obesity -- what do we really know?
Social and economic factors have led to a dramatic rise in type 2 diabetes and obesity around the world.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
New cause of diabetes
Although insulin-producing cells are found in the endocrine tissue of the pancreas, a new mouse study suggests that abnormalities in the exocrine tissue could cause cell non-autonomous effects that promotes diabetes-like symptoms.
The Lancet Diabetes & Endocrinology: Reducing sugar content in sugar-sweetened drinks by 40 percent over 5 years could prevent 1.5 million cases of overweight and obesity in the UK and 300,000 cases of diabetes
A new study published in The Lancet Diabetes & Endocrinology journal suggests that reducing sugar content in sugar sweetened drinks (including fruit juices) in the UK by 40 percent over five years, without replacing them with any artificial sweeteners, could prevent 500,000 cases of overweight and 1 million cases of obesity, in turn preventing around 300,000 cases of type 2 diabetes, over two decades.
Breastfeeding lowers risk of type 2 diabetes following gestational diabetes
Women with gestational diabetes who consistently and continuously breastfeed from the time of giving birth are half as likely to develop type 2 diabetes within two years after delivery, according to a study from Kaiser Permanente published today in Annals of Internal Medicine.

Related Diabetes Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".